Clinical trials: Stage III Skin Cancer
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
This phase II clinical trial tests how well rigosertib plus pembrolizumab workings in treating patients with melanoma which cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site)…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma
- Trial name
- NCT05764395
- Testing
- Rigosertib, Pembrolizumab, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, Inflammatory Breast Cancer
MUC1 Vaccine for Triple-negative Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.
- Conditions
- Breast Cancer, Inflammatory Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00986609
- Testing
- MUC-1 peptide vaccine, poly ICLC, MUC1 peptide-poly-ICLC adjuvant vaccine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Joseph Baar, MD, PhD
Breast Cancer, Colorectal Cancer
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
RATIONALE: Identification of genes that may be associated with developing certain types of cancer may someday provide important information about a person's risk of getting cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003329
- Testing
- gene mapping
- Where
- 32 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer, Stage 0 Breast Cancer
A Study of Revaree Plus in People With Breast Cancer
The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.
- Conditions
- Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT07042581
- Testing
- Revaree Plus
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
This clinical trial compares a web-based patient-reported symptom monitoring and self management portal, the Young, Empowered \& Strong (YES), to standard therapy in managing symptoms in adolescent and young adult breast cancer…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- YES (NCT04906200)
- Testing
- Best Practice, Internet-Based Intervention, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer, Breast Cancer Female
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
This is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.
- Conditions
- Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer, Breast Cancer Stage II
- Trial name
- NCT03879577
- Testing
- Docetaxel, Herceptin, FEC
- Where
- Nigeria
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Breast Cancer, Breast Cancer Stage I
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer…
- Conditions
- Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT06268665
- Testing
- Tart Cherry Juice
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- University of California, Davis
HER2-positive Locally Advanced or Metastatic Breast Cancer
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer…
- Trial name
- PRECIOUS (NCT02514681)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 3 sites in Japan
- Volunteers
- 226 people
- Sponsor
- Japan Breast Cancer Research Group
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Female, Stage I Breast Cancer
Living Well After Breast Surgery
Decision making about whether to have breast reconstruction after mastectomy can be difficult, and previous studies have found that many women are not well informed about their options.
- Conditions
- Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT03834532
- Testing
- Breast reconstruction decision aid, Educational website
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas at Austin
Melanoma
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients
Objectives: This is an exploratory study, consisting of two parts. In part I dose escalation is performed and the primary objective is the safety of different doses of TLR-DC and Trimix DC.
- Trial name
- NCT01530698
- Testing
- autologous dendritic cell vaccine
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Radboud University Medical Center
Breast Cancer, Cancer Survivor
The Impact of Lymphedema on Breast Cancer Survivors
RATIONALE: Gathering information from breast cancer survivors about lymphedema; its symptoms and their impact on shoulder, arm, and hand functioning; and quality of life may help doctors learn more about the disease.
- Conditions
- Breast Cancer, Cancer Survivor, Lymphedema, Perioperative/Postoperative Complications
- Trial name
- NCT00769821
- Testing
- questionnaire administration, assessment of therapy complications, bioimpedance spectroscopy
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- University of California, San Francisco
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to…
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma
- Trial name
- NCT00085189
- Testing
- gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Southern California
Locally Advanced Breast Cancer, Breast Cancer
Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca
Women with breast cancer undergo treatments that decrease the chance of recurrence of cancer, but are associated with several side effects, including declines in memory and attention and other thinking abilities.
- Trial name
- Cyto-Cog (NCT00756132)
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Melanoma (Skin)
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00091143
- Testing
- gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Providence Cancer Center, Earle A. Chiles Research Institute
Breast Cancer, Sentinel Lymph Node
No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography
NAUTILUS study is a prospective, multicenter, RCT. Clinically T1,T2, node negative BCS candidates with no evidence of metastases in AUS are 1:1 randomized into no SLNB group and SLNB group.
- Trial name
- NCT04303715
- Testing
- No SLNB, SLNB
- Where
- South Korea
- Volunteers
- 1,734 people
- Sponsor
- Seoul National University Hospital
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
This phase II trial compares the effect of adding darolutamide to standard therapy versus standard therapy alone before surgery for the treatment of patients with stage II-IIIA androgen receptor positive triple-negative breast…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07016399
- Testing
- Biospecimen Collection, Breast Biopsy Procedure, Carboplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Vandana Abramson
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Chemotherapy, Adjuvant
Adjuvant FEC Versus EP in Breast Cancer (MIG5)
In this multicenter, randomized phase III trial, node positive early breast cancer patients are randomly assigned to receive either 6 cycles of FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, on…
- Trial name
- MIG5 (NCT02450058)
- Testing
- 5-fluorouracil, epirubicin, cyclophosphamide
- Where
- 8 sites in Italy
- Volunteers
- 1,055 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.